Galapagos (GB:0JXZ) has released an update.
Galapagos NV has announced that the FDA approved their IND application for a phase 1/2 study, ATALANTA-1, to assess their CD19 CAR-T cell therapy candidate, GLPG5101, in patients with relapsed/refractory non-Hodgkin lymphoma. The study aims to evaluate the safety, efficacy, and feasibility of GLPG5101, which is produced using an innovative decentralized manufacturing platform promising faster delivery of treatment. Initial European data for the ongoing study appears promising, bringing hope for rapid advancements in treatment for US patients.
For further insights into GB:0JXZ stock, check out TipRanks’ Stock Analysis page.
